Market Place
Sourcing Support
Polaris Pharmacy Becomes Exclusive US Distributor of FluMist
21 Aug 2025 //
BUSINESSWIRE
AstraZeneca Starts DTC Home Delivery of FluMist Vaccine
15 Aug 2025 //
FIERCE PHARMA
Nectar Lifesciences Unit VI Earns CGMP Certification from SMDC
12 Aug 2025 //
EQUITYBILL
AZ`s Alexion Highlights gMG in Upcoming Awareness Film
31 Jul 2025 //
FIERCE PHARMA
Symbiosis Achieves 1,000th Injectable Drug Batch Milestone
31 Jul 2025 //
EXPRESSPHARMA
Imfinzi Gets Priority Review, Breakthrough Therapy Status in US
31 Jul 2025 //
INDPHARMAPOST
Trixeo Gets Positive EU CHMP Nod as First GWP Inhaled Medicine
31 Jul 2025 //
INDPHARMAPOST
AstraZeneca, Revna Boost Lung Cancer Treatment Access in Ghana
30 Jul 2025 //
BUSINESSWIRE
AstraZeneca H1 and Q2 2025 Results
29 Jul 2025 //
BUSINESSWIRE
AstraZeneca Abandons Lead TCR Therapy in $200M Neogene Purchase
29 Jul 2025 //
FIERCE BIOTECH
Imfinzi Gets US Priority Review for Early-Stage Gastric Cancers
28 Jul 2025 //
BUSINESSWIRE
AstraZeneca`s Rare Immune Disorder Drug Succeeds in Trial
25 Jul 2025 //
REUTERS
AstraZeneca`s Immune Disorder Drug Succeeds in Late-Stage Trial
24 Jul 2025 //
REUTERS
AstraZeneca Launches Tagrisso Lung Cancer TV Ad
23 Jul 2025 //
FIERCE PHARMA
AstraZeneca Unveils $50 B US Investment as Pharma Tariff Threat
22 Jul 2025 //
REUTERS
AstraZeneca Touts Life-Extension Benefit for Tagrisso Combo
22 Jul 2025 //
PRESS RELEASE
Enhertu + Pertuzumab Get US BTD for HER2+ Breast Cancer
17 Jul 2025 //
BUSINESSWIRE
AstraZeneca for Clearing Protein Fails Main Goal in Late-Stage
17 Jul 2025 //
PRESS RELEASE
Real Chemistry Appoints Three to Catalyze Change
16 Jul 2025 //
FIERCE PHARMA
AstraZeneca Gains CDSCO Approval for Treatment of Bladder Cancer
15 Jul 2025 //
EXPRESSPHARMA
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase 3
15 Jul 2025 //
PRESS RELEASE
Eolas Therapeutics Secures Full Development Rights to AZD4041
10 Jul 2025 //
BUSINESSWIRE
Respiratory Royalty Rally Around Rural COPD Education Drive
09 Jul 2025 //
FIERCE PHARMA
AstraZeneca Inks Third Deal with JCR Pharma For Gene Therapies
09 Jul 2025 //
PRESS RELEASE
Summit, Astrazeneca in Talks Over 15 B Cancer Drug Licensing Deal
05 Jul 2025 //
REUTERS
Imfinzi Approved in EU as First Perioperative Immunotherapy
04 Jul 2025 //
PRESS RELEASE
Modella AI to Advance Oncology Trials With AI Agreement
02 Jul 2025 //
BUSINESSWIRE
Soriot plots move of AZ stock listing to US: The Times
02 Jul 2025 //
FIERCE PHARMA
AstraZeneca Pharma India Approved for Endometrial Cancer
02 Jul 2025 //
EXPRESSPHARMA
Onco-Innovations Welcomes AstraZeneca`s Interest in PROmAI
27 Jun 2025 //
ACCESSWIRE
AstraZeneca Expands Bengaluru Hub with ?166 Cr Investment
26 Jun 2025 //
ECONOMICTIMES
US CDC vaccine panel postpones vote on RSV therapies
25 Jun 2025 //
REUTERS
DATROWAY® approved in US for advanced EGFR-mutated lung cancer
24 Jun 2025 //
BUSINESSWIRE
BMJ Finds More Irregularities in Trial Data for Az`s Brilinta
24 Jun 2025 //
FIERCE PHARMA
Datroway approved in US as first TROP2 Therapy for Lung Cancer
23 Jun 2025 //
BUSINESSWIRE
Eccogene Starts Phase 1b Trial of AZD5004/ECC5004 in China
18 Jun 2025 //
GLOBENEWSWIRE
Sheffield & Astra Zeneca Develop for Inverse Protein Folding
18 Jun 2025 //
EXPRESSPHARMA
AZ touts Ultomiris Results in Post-Transplant Complication Trial
17 Jun 2025 //
FIERCE PHARMA
AstraZeneca Signs AI Research Deal with CSPC for Chronic Disease
14 Jun 2025 //
REUTERS
Syntimmune Shareholders Win Again Over AZ, time for $181M
13 Jun 2025 //
FIERCE BIOTECH
Quell Therapeutics Hits Milestone in CAR-Treg for IBD
10 Jun 2025 //
GLOBENEWSWIRE
IonQ accelerates drug development with AstraZeneca, AWS, NVIDIA
09 Jun 2025 //
BUSINESSWIRE
Enhertu Phase 3 Trial Begins for HER2+ Endometrial Cancer
09 Jun 2025 //
BUSINESSWIRE
EU Approves Calquence-Based Regimens for CLL Patients
07 Jun 2025 //
PRESS RELEASE
SERENA-6 Trial Shows Guardant360 CDx Test Value in Breast Cancer
02 Jun 2025 //
BUSINESSWIRE
Enhertu+Pertuzumab Cuts Risk 44% in HER2+ Breast Ca Ph3
02 Jun 2025 //
BUSINESSWIRE
Camizestrant Reduced Risk of Disease Progression or Death by 56%
02 Jun 2025 //
BUSINESSWIRE
Camizestrant Cuts Risk 56% In ESR1+ HR+ Breast Cancer Trial
01 Jun 2025 //
BUSINESSWIRE
Imfinzi Regimen Cuts Progression Risk 29% In Gastric Cancer
01 Jun 2025 //
BUSINESSWIRE
Datroway Shows Promising Tumor Responses in Lung Cancer
01 Jun 2025 //
BUSINESSWIRE
Enhertu Reduces Death Risk by 30% vs Ramucirumab Plus Paclitaxel
31 May 2025 //
BUSINESSWIRE
AstraZeneca Settles for $51 Million in Seroquel Antitrust Case
30 May 2025 //
REUTERS
Pfizer-Arvinas Breast Cancer Drug tops AstraZeneca
30 May 2025 //
REUTERS
AstraZeneca India approved for new use of Osimertinib
29 May 2025 //
EXPRESSPHARMA
Enforcement Report - Week of May 28, 2025
28 May 2025 //
FDA
Zentiva Inks 220M Deal for Former Astra Zeneca GI Drug in Europe
22 May 2025 //
FIERCE PHARMA
AZ, Merck Duke It out To Lead Oncologists’ Pharma Perceptions
22 May 2025 //
FIERCE PHARMA
Aptar Digital Health, AstraZeneca Partner on AI Screening
22 May 2025 //
BUSINESSWIRE
AstraZeneca`s record year at ASCO Advances Cancer Care
21 May 2025 //
BUSINESSWIRE
IDEA ranks Lilly, AZ as biopharma`s top Innovators, Inventors
20 May 2025 //
FIERCE PHARMA
